Has Wade Nishimoto received payments from drug or device companies?

Yes. Drug and device makers reported $12,816 in general payments to Wade Nishimoto across 536 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wade Nishimoto did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wade Nishimoto come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wade Nishimoto

Hematology & Oncology · Los Angeles, CANPI 1083641518

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,873 of the $12,816 with a category attached, or 84.8%. It is spread thinly across 54 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations.

$12,816in general payments, 2019–2025

Across 536 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$2K
E.r. Squibb & Sons, L.L.C.$1K
Genentech USA, Inc.$752
AstraZeneca$719
Bayer$634
Amgen$625
plus $7K from 48 others

What the payments were for

Consulting fees$1,70013%
Food & beverage$10,87385%
Education$2432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead(2 entities)	9	$1,909
E.r. Squibb & Sons, L.L.C.	69	$1,171
Genentech USA, Inc.	34	$752
AstraZeneca(2 entities)	31	$719
Bayer	29	$634
Amgen	23	$625
Pfizer	35	$498
Novartis	26	$467
Seagen Inc.	15	$461
Astellas Pharma US Inc	20	$435
Bristol Myers Squibb	18	$421
Sanofi	19	$396
Incyte Corporation	19	$364
Merck	18	$343
Eisai Inc.	21	$320
Pharmacyclics LLC, An Abbvie Company	12	$313
Exelixis Inc.	11	$297
Karyopharm Therapeutics Inc.	11	$253
Johnson & Johnson(2 entities)	14	$233
Boehringer Ingelheim	8	$175
EMD Serono, Inc.	8	$150
Tesaro, Inc.	5	$143
Lilly USA, LLC	7	$132
Taiho Oncology, Inc.	5	$128
Epizyme, Inc.	5	$112
Ipsen Biopharmaceuticals, Inc	4	$109
Daiichi Sankyo Inc.	5	$103
Tersera Therapeutics LLC	3	$88
Lexicon Pharmaceuticals, Inc.	4	$84
Takeda Pharmaceuticals U.S.A., Inc.	3	$83
Blueprint Medicines Corporation	3	$81
AbbVie	3	$62
GSK	2	$54
Teva Pharmaceuticals USA, Inc.	3	$52
Rigel Pharmaceuticals, Inc.	2	$51
Helsinn Therapeutics (U.S.), Inc.	3	$51
Agios Pharmaceuticals, Inc.	2	$48
Regeneron Healthcare Solutions, Inc.	2	$46
Puma Biotechnology, Inc.	2	$46
EUSA Pharma (US) LLC	3	$46
Jazz Pharmaceuticals Inc.	2	$45
Advanced Accelerator Applications	3	$44
Verastem, Inc.	2	$41
Global Blood Therapeutics, Inc.	2	$34
Chiesi USA, Inc.	2	$29
AMAG Pharmaceuticals, Inc.	1	$23
Shionogi Inc	1	$23
Apo-pharma USA, Inc.	1	$21
Dova Pharmaceuticals	1	$20
Kyowa Kirin, Inc.	1	$18
Deciphera Pharmaceuticals Inc.	1	$18
Clovis Oncology, Inc.	1	$17
Shire North American Group Inc	1	$14
Tactile Systems Technology Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tecartus$1,700
Herceptin$150
TECENTRIQ$150
TUKYSA$125
OPDIVO$122
Nplate$121
Nubeqa$119

How this compares

$12,816 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Other hematology & oncology in Los Angeles

Dennis SlamonLos Angeles$3.1M
George YaghmourLos Angeles$1.9M
Kevin KellyLos Angeles$894K
Raghuveer RanganathanLos Angeles$609K
Matthew RettigLos Angeles$442K
David BerzLos Angeles$420K
Gottfried KonecnyLos Angeles$402K
Antoni RibasLos Angeles$315K
Edward GaronLos Angeles$301K
Rahul NaikLos Angeles$297K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →